Skip to main content

Scientists Discover Way to Send Information into Black Holes Without Using Energy

3 comments

Scientists Discover a Drug That Reversed Severe Fatty Liver Disease by Healing the Gut

Scientists have discovered a promising new approach to treating severe fatty liver disease by targeting an unexpected source of damage: the gut. An experimental drug called DT-109 reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal studies by reducing harmful gut bacteria, repairing the intestinal barrier, and preventing inflammatory substances from reaching the liver.

The findings, published in The Journal of Clinical Investigation, could open the door to new treatments for a condition that affects millions of people worldwide. The research also highlights how improving gut health may help protect other organs, including the heart and blood vessels.

Although the results are encouraging, DT-109 remains an experimental drug. Its safety and effectiveness in humans must be established through further clinical research.

What Is Fatty Liver Disease, and Why Is It Dangerous?

Fatty liver disease develops when too much fat accumulates inside the liver. In some people, this buildup can trigger inflammation and damage liver cells, eventually leading to a more serious condition known as MASH.

MASH can gradually cause liver scarring, a process called fibrosis. In advanced cases, it may progress to cirrhosis, liver failure, or liver cancer.

The condition affects approximately 7% of the global population, according to the research background. It is closely associated with metabolic problems, including obesity, insulin resistance, and type 2 diabetes.

Although treatment options have improved, managing advanced fatty liver disease remains challenging. This has encouraged scientists to explore new approaches that address the biological processes responsible for the condition.

The new research suggests that the answer may lie partly in the digestive system rather than in the liver alone.

How Harmful Gut Bacteria Can Damage the Liver

The human gut contains trillions of microorganisms, including bacteria that help digest food and support normal body functions. However, changes in the balance of these microorganisms can sometimes contribute to disease.

Scientists have discovered that a bacterium called Clostridium perfringens may play an important role in the development of MASH. This bacterium can produce ammonia in the intestines, and excessive ammonia may damage the protective lining of the gut.

Under normal conditions, the intestinal lining acts as a barrier. It allows nutrients to pass into the body while helping prevent harmful substances from entering the bloodstream.

When this barrier becomes weakened, microbial products and other inflammatory substances can escape from the intestine and travel to the liver.

The liver receives blood from the digestive system through the portal circulation, making it particularly vulnerable to substances absorbed from the gut.

Once these harmful products reach the liver, they can trigger inflammation and worsen existing tissue damage. The process can also activate CD8+ T cells, immune cells that normally help fight infections and abnormal cells.

When these immune cells become excessively activated, they can contribute to the inflammation associated with MASH.

This chain of events helps explain how changes in gut bacteria can contribute to liver disease, even though the damage occurs in another organ.

How DT-109 Interrupts the Damage

DT-109 is an experimental compound developed by researchers at the University of Michigan's Michigan Medicine. It is a glycine-based tripeptide, meaning it is a small molecule made from three amino acids.

Researchers had previously found that DT-109 could improve MASH in animal studies. However, they wanted to understand exactly how the compound produced these benefits.

The latest study provides a clearer explanation.

Scientists found that DT-109 helps reduce harmful Clostridium perfringens bacteria and lowers ammonia production in the intestines. This helps protect the intestinal lining and reduces the movement of harmful microbial substances into the bloodstream.

As a result, fewer inflammatory substances can reach the liver and contribute to tissue damage.

In simple terms, the drug appears to interrupt a harmful cycle: gut bacteria produce substances that weaken the intestinal barrier, the weakened barrier allows inflammatory products to escape, and those products contribute to liver inflammation.

By improving the gut environment, DT-109 may help prevent this chain reaction before it causes further damage.

The findings support the importance of the gut-liver axis, the biological connection through which the digestive system and liver influence each other's health.

Promising Results in Mice and Nonhuman Primates

The research team tested DT-109 in mice and nonhuman primates. In these animal models, the compound reduced harmful bacteria, lowered intestinal ammonia levels, and helped strengthen the gut barrier.

The researchers also observed improvements in liver inflammation and MASH severity in nonhuman primates.

These results are particularly interesting because nonhuman primates share several biological features with humans, including aspects of liver function and gut microbial communities.

However, successful results in animals do not guarantee that a drug will work equally well in people. Differences in metabolism, immune responses, and disease progression can influence how a treatment performs in human patients.

Further studies will therefore be necessary to determine whether DT-109 can deliver similar benefits in people with severe fatty liver disease.

Could the Drug Also Protect the Heart?

The potential benefits of DT-109 may extend beyond the liver.

Previous research has suggested that the compound can reduce the formation of atherosclerotic plaques and prevent vascular calcification in nonhuman primates.

Atherosclerotic plaques develop when fat, cholesterol, and other substances accumulate inside artery walls. Over time, these deposits can narrow arteries and increase the risk of heart attacks and strokes.

Vascular calcification occurs when calcium deposits build up in blood vessel walls, potentially making them stiffer and less flexible.

These findings raise the possibility that DT-109 could eventually help address several conditions associated with metabolic dysfunction.

The connection is important because fatty liver disease and cardiovascular disease often share underlying risk factors, including obesity, insulin resistance, and abnormal fat metabolism.

Nevertheless, the earlier animal findings do not establish that DT-109 prevents heart attacks, strokes, or other cardiovascular events in humans. Clinical trials would be needed to investigate these possibilities.

Could It Help Other Gut Disorders?

Researchers are also interested in exploring whether DT-109 could benefit people with inflammatory bowel disease (IBD), a group of chronic conditions that includes Crohn's disease and ulcerative colitis.

These disorders can involve inflammation and damage to the intestinal lining. Because DT-109 appears to strengthen the gut barrier in animal studies, it may offer a potential research direction for conditions involving intestinal dysfunction.

However, its effectiveness against IBD has not been established. Additional experiments would be needed to determine whether the drug provides meaningful benefits for these patients.

What Happens Next?

Despite the promising findings, DT-109 is not yet an established treatment for human fatty liver disease.

Researchers must determine the appropriate dose, evaluate potential side effects, and establish whether the compound can safely produce lasting improvements in patients.

The research also has a financial connection worth noting. University of Michigan researchers, including senior author Eugene Chen, are listed as inventors associated with DT-109 and related patent applications. The university holds the patent for the compound and has licensed it to Diapin Therapeutics, which supplied DT-109 for the research and is continuing its development.

This relationship does not invalidate the findings, but it is relevant when evaluating the research and understanding the commercial development of the drug.

A New Way to Think About Liver Disease

The study highlights an important shift in the search for treatments for fatty liver disease. Instead of focusing exclusively on the liver, scientists are investigating how harmful gut bacteria and damage to the intestinal barrier can contribute to the condition.

By reducing harmful bacteria and limiting the movement of inflammatory substances from the gut into the bloodstream, DT-109 may help protect the liver through a mechanism that begins in the digestive system.

If future human trials confirm the benefits observed in animals, the compound could eventually offer a new treatment option for people with MASH. Its possible effects on cardiovascular health and other inflammatory conditions could also make it an important subject for further research.

For now, the discovery provides promising evidence that healing the gut may be one way to protect the liver. The next challenge is determining whether this approach can safely and effectively help patients.

Reference:

  1. Pengxiang Qu, Shusi Ding, Yanru Zhang, Yang Zhao, Erfei Song, Liangshuo Hu, Ruike Ding, Wenbin Cao, Yiting Hou, Jia Qi, Juan Zhao, Chenjing Duan, Shuangqing Liu, Chong Shen, Ying Zhao, Yanhong Guo, Zuowen Zheng, Shiwei Luo, Huizhong Hu, Liang Bai, Sihai Zhao, Bo Wang, Shuixiang He, Yi Wu, Xuelian Xiong, Qiutong Wu, Weiwang Gu, Oren Rom, Aimin Xu, Lemin Zheng, Jifeng Zhang, Enqi Liu, Y. Eugene Chen. Metabolic dysfunction–associated steatohepatitis exacerbated by Clostridium perfringens–derived ammonia is attenuated by tripeptide DT-109. Journal of Clinical Investigation, 2026; 136 (13) DOI: 10.1172/JCI200522

Comments

Post a Comment

Popular

Scientists Discover Way to Send Information into Black Holes Without Using Energy

For years, scientists believed that adding even one qubit (a unit of quantum information) to a black hole needed energy. This was based on the idea that a black hole’s entropy must increase with more information, which means it must gain energy. But a new study by Jonah Kudler-Flam and Geoff Penington changes that thinking. They found that quantum information can be teleported into a black hole without adding energy or increasing entropy . This works through a process called black hole decoherence , where “soft” radiation — very low-energy signals — carry information into the black hole. In their method, the qubit enters the black hole while a new pair of entangled particles (like Hawking radiation) is created. This keeps the total information balanced, so there's no violation of the laws of physics. The energy cost only shows up when information is erased from the outside — these are called zerobits . According to Landauer’s principle, erasing information always needs energy. But ...
3 comments
Read more

Black Holes That Never Dies

Black holes are powerful objects in space with gravity so strong that nothing can escape them. In the 1970s, Stephen Hawking showed that black holes can slowly lose energy by giving off tiny particles. This process is called Hawking radiation . Over time, the black hole gets smaller and hotter, and in the end, it disappears completely. But new research by Menezes and his team shows something different. Using a theory called Loop Quantum Gravity (LQG) , they studied black holes with quantum corrections. In their model, the black hole does not vanish completely. Instead, it stops shrinking when it reaches a very small size. This leftover is called a black hole remnant . They also studied something called grey-body factors , which affect how much energy escapes from a black hole. Their findings show that the black hole cools down and stops losing mass once it reaches a minimum mass . This new model removes the idea of a “singularity” at the center of the black hole and gives us a better ...
Post a Comment
Read more

How Planetary Movements Might Explain Sunspot Cycles and Solar Phenomena

Sunspots, dark patches on the Sun's surface, follow a cycle of increasing and decreasing activity every 11 years. For years, scientists have relied on the dynamo model to explain this cycle. According to this model, the Sun's magnetic field is generated by the movement of plasma and the Sun's rotation. However, this model does not fully explain why the sunspot cycle is sometimes unpredictable. Lauri Jetsu, a researcher, has proposed a new approach. Jetsu’s analysis, using a method called the Discrete Chi-square Method (DCM), suggests that planetary movements, especially those of Earth, Jupiter, and Mercury, play a key role in driving the sunspot cycle. His theory focuses on Flux Transfer Events (FTEs), where the magnetic fields of these planets interact with the Sun’s magnetic field. These interactions could create the sunspots and explain other solar phenomena like the Sun’s magnetic polarity reversing every 11 years. The Sun, our closest star, has been a subject of scient...
Post a Comment
Read more